¥1,746.00
0.23% yesterday
Tokyo, Nov 07, 07:15 am CET
ISIN
JP3942400007
Symbol
4503
Index

Astellas Pharma Stock price

¥1,752.50
+90.50 5.45% 1M
+321.00 22.42% 6M
+218.00 14.21% YTD
+18.00 1.04% 1Y
-308.00 14.95% 3Y
+171.50 10.85% 5Y
-49.50 2.75% 10Y
+906.50 107.15% 20Y
Tokyo, Closing price Fri, Nov 07 2025
+10.50 0.60%
ISIN
JP3942400007
Symbol
4503
Index
Industry

New AI Insights on Astellas Pharma Insights AI Insights on Astellas Pharma

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
¥3.1t
Enterprise Value
¥3.7t
Net debt
¥444.8b
Cash
¥295.7b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
38.3 | 17.4
P/S
1.6 | 1.5
EV/Sales
1.9 | 1.8
EV/FCF
19.6
P/B
2.1
Dividends
DPS
¥78.00
Yield 1Y | 5Y
4.5% | 3.7%
Growth 1Y | 5Y
5.4% | 13.2%
Payout 1Y | 3Y
262.0% | 222.2%
Increased
14 Years
Financials (TTM | estimate)
Revenue
¥2.0t | ¥2.0t
EBITDA
¥278.9b | ¥452.9b
EBIT
¥145.8b | ¥441.9b
Net Income
¥124.9b | ¥179.5b
Free Cash Flow
¥334.6b
Growth (TTM | estimate)
Revenue
13.2% | 5.1%
EBITDA
9.5% | 13.2%
EBIT
21.1% | 67.7%
Net Income
128.1% | 253.7%
Free Cash Flow
168.9%
Margin (TTM | estimate)
Gross
81.3%
EBITDA
13.9% | 22.5%
EBIT
7.3%
Net
6.2% | 8.9%
Free Cash Flow
16.7%
Financial Health
Equity Ratio
45.3%
Return on Equity
3.4%
ROCE
6.9%
ROIC
5.9%
Debt/Equity
0.5
More
EPS
¥69.7
FCF per Share
¥186.8
Short interest
-
Employees
15k
Rev per Employee
¥129.6m
Show more

Is Astellas Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Astellas Pharma Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Astellas Pharma forecast:

9x Buy
45%
10x Hold
50%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a Astellas Pharma forecast:

Buy
45%
Hold
50%
Sell
5%

Financial data from Astellas Pharma

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,006,816 2,006,816
13% 13%
100%
- Direct Costs 375,740 375,740
16% 16%
19%
1,631,076 1,631,076
13% 13%
81%
- Selling and Administrative Expenses 840,455 840,455
6% 6%
42%
- Research and Development Expense 298,610 298,610
8% 8%
15%
278,865 278,865
9% 9%
14%
- Depreciation and Amortization 133,020 133,020
1% 1%
7%
EBIT (Operating Income) EBIT 145,845 145,845
21% 21%
7%
Net Profit 124,871 124,871
128% 128%
6%

In millions JPY.

Don't miss a Thing! We will send you all news about Astellas Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Naoki Okamura
Employees 14,754
Founded 1923
Website www.astellas.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today